Emerging at the UK, retatrutide, a new compound , is sparking considerable buzz within the scientific community regarding its potential for physique management . This dual GIP and GLP-1 agent agonist looks to offer a significant benefit over established therapies, showing promising results in initial clinical assessments. Researchers suggest its di